United States

Northwest Biotherapeutics initiates phase I/II trial

Friday, June 14, 2013 01:38 PM

Northwest Biotherapeutics, a developer of non-toxic DCVax personalized immune therapies for solid tumor cancers, has announced  its 60-patient, phase I/II clinical trial of DCVax-Direct for all inoperable solid tumor cancers has been initiated at The University of Texas MD Anderson Cancer Center.

More... »

MEI Pharma appoints Nick Glover to board of directors

Friday, June 14, 2013 01:35 PM

MEI Pharma, an oncology company focused on the clinical development of novel therapies for cancer, has appointed Nick Glover, Ph.D., to its board of directors, increasing the board to seven members, including six independent directors.

More... »

Saladax receives CLIA certification and approval

Friday, June 14, 2013 01:34 PM

Saladax Biomedical, a privately held company developing novel diagnostic tests that individually optimize a patient's exposure to chemotherapy, has been certified as a registered CLIA laboratory from the Office of Clinical Standards and Quality (OCSQ), a division of The Centers for Medicare & Medicaid Services (CMS) that regulates laboratory testing performed on humans. The CLIA certification and approval allows the company to begin clinical laboratory operations for the MyCare portfolio of products at its facilities in Bethlehem, Pa.

More... »

SynteractHCR launches platform to support trial efficiencies

Friday, June 14, 2013 09:31 AM

San Diego-based SynteractHCR, a full-service CRO, will unveil its Intelligent Clinical Development platform (ICD+) at the upcoming DIA annual meeting in Boston. 

More... »

Dockhorn joins SCORR Marketing

Thursday, June 13, 2013 04:01 PM

Michelle Dockhorn, M.B.A., Ph.D., an executive with extensive marketing and business development leadership experience specific to the life science industry, has joined SCORR Marketing as vice president of global markets. Dockhorn brings 20 years of experience to SCORR.

More... »

CTI Clinical Trial and Consulting Services, Galectin Therapeutics collaborate

Thursday, June 13, 2013 02:03 PM

CTI Clinical Trial and Consulting Services (CTI), an international drug and device development organization, will collaborate with Galectin Therapeutics on a first-in-man phase I clinical trial  of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH) with advanced fibrosis.

More... »

DigiCert, DataMotion partner for secure health information exchange

Thursday, June 13, 2013 11:30 AM

DigiCert, a high-assurance digital certificate provider, and DataMotion, a health information service provider (HISP) with 14 years of experience in secure data delivery services, have partnered to expand common dual-mode certification for commercial and federal use for the healthcare industry. The partnership plans to improve patient care by making it much simpler for federal and non-federal organizations to engage in the secure electronic exchange of healthcare information.

More... »

Paul M. Karpecki joins Freedom Meditech scientific advisory board

Thursday, June 13, 2013 10:00 AM

Freedom Meditech, a medical device company commercializing non-invasive ophthalmic technologies for the detection of disease and management of patient health, has appointed Paul M. Karpecki, OD, FAAO, to the scientific advisory board.

More... »

Viatronix V3D-Colon software used in trial

Wednesday, June 12, 2013 02:44 PM

Viatronix, a maker of non-invasive 2D/3D medical imaging and diagnostic software, said its dedicated CT Colonography (CTC) software, V3D-Colon, was exclusively used in a clinical study relating to colorectal cancer screening. The latest CTC study tracked polyp growth in 243 patients over an eight-year period.

More... »

Renée Bell named Neurovations’ director of clinical research

Wednesday, June 12, 2013 02:40 PM

Neurovations, a clinical research and consulting company in pain management and neuroscience, has named Renée Bell director of clinical research. Bell brings 25 years of experience to Neurovations, with work in expanding research operations, particularly in the pharmaceutical industry.

More... »